Ameriprise’s IGC Pharma IGC Stock Holding History

Ameriprise’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,000	Closed	-$16K	–	3733
2019 Q2	$16K	Buy	+10,000	New	+$14.1K	﹤0.01%	3704

Other funds holding IGC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CFA

Carroll Financial Associates Charlotte, North Carolina $1.88B AUM 20.52% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ameriprise's IGC Position: Q3 2019 in Review

Ameriprise sold out of IGC Pharma (IGC) in Q3 2019, closing a stake of 10,000 shares — an estimated $16K sold.

Ameriprise first reported a position in IGC in Q2 2019 and held it in 1 quarter. The position peaked at $16K in Q2 2019. 26 funds tracked by Wall St. Rank hold IGC as of Q3 2019.

Ameriprise reported no remaining IGC Pharma position as of Q3 2019 after selling out during the quarter.
Ameriprise sold 10,000 IGC Pharma shares in Q3 2019, an estimated $16K.
Ameriprise first reported a position in IGC Pharma in Q2 2019 and held it in 1 quarter.
Ameriprise's IGC Pharma position peaked at $16K in Q2 2019.
26 funds tracked by Wall St. Rank held IGC Pharma as of Q3 2019.

Based on Ameriprise's 13F filing for Q3 2019, filed 14 Nov 2019.